About FibroGen (NASDAQ:FGEN)
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200
Debt
Debt-to-Equity Ratio0.19
Current Ratio8.61
Quick Ratio8.61
Price-To-Earnings
Trailing P/E Ratio-34.42
Forward P/E Ratio-37.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$125.67 million
Price / Sales39.74
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book8.43
Profitability
EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-102.86%
Return on Equity-27.70%
Return on Assets-16.78%
Miscellaneous
Employees423
Outstanding Shares83,520,000
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.01. The biopharmaceutical company had revenue of $31.90 million for the quarter, compared to the consensus estimate of $29.07 million. FibroGen had a negative return on equity of 27.70% and a negative net margin of 102.86%. The business's revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.48) earnings per share. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
7 brokers have issued 1 year price targets for FibroGen's stock. Their forecasts range from $31.00 to $88.00. On average, they anticipate FibroGen's share price to reach $66.6667 in the next year. View Analyst Ratings for FibroGen.
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (6/15/2018)
- 2. Mizuho analysts commented, "We expect to see top-line phase 3 data from Disease (CKD) in 4Q18 and a potential regulatory approval in China is expected by year-end 2018. We upgrade to Buy and maintain our $61 PT as we believe the company is likely to gain the first approval in new generation anemia drugs. If Pamrevlumab reproduces its Phase II results in the planned Phase III trial, we see significant upside." (5/15/2018)
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE) and Sarepta Therapeutics (SRPT).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
- Mr. Pat Cotroneo, Chief Financial Officer (Age 54)
- Dr. K. Peony Yu, Chief Medical Officer (Age 56)
- Mr. Julian N. Stern, Sec. (Age 93)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Has FibroGen been receiving favorable news coverage?
Media headlines about FGEN stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. FibroGen earned a coverage optimism score of 0.08 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.09%), Farallon Capital Management LLC (2.06%), JPMorgan Chase & Co. (1.16%), Northern Trust Corp (1.00%), Eagle Asset Management Inc. (0.98%) and Lord Abbett & CO. LLC (0.69%). Company insiders that own FibroGen stock include Gerald Lema, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which institutional investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Sphera Funds Management LTD., Citigroup Inc., Nexthera Capital LP, Wells Fargo & Company MN, Pinnacle Associates Ltd. and Dimensional Fund Advisors LP. Company insiders that have sold FibroGen company stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff and Thomas F Kearns Jr. View Insider Buying and Selling for FibroGen.
Which institutional investors are buying FibroGen stock?
FGEN stock was bought by a variety of institutional investors in the last quarter, including PointState Capital LP, Artal Group S.A., UBS Group AG, Amundi Pioneer Asset Management Inc., Lord Abbett & CO. LLC, BNP Paribas Arbitrage SA, Millennium Management LLC and Prudential Financial Inc.. View Insider Buying and Selling for FibroGen.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $59.80.
How big of a company is FibroGen?
FibroGen has a market capitalization of $4.92 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
